Saturday, April 27, 2024, Washington, DC, 6:00 AM – 7:30 AM Eastern Time

What I Tell My Patients: Integrating New Research Information into Current Clinical Care

A Complimentary NCPD Hybrid Symposium Series Held During the 49th Annual ONS Congress

Hepatobiliary Cancers

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Program Schedule — Eastern Time
5:30 AM – 6:00 AM — Registration
6:00 AM – 7:30 AM — NCPD Breakfast Meeting

Meeting Room
Independence Ballroom (Meeting Level 4)

This event will also be webcast live.
Please see Registration tab for details.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.  
Blanca Ledezma, MSN, NP, AOCNP
UCLA Santa Monica Hematology/Oncology
Santa Monica, California

Stacey Stein, MD
Associate Professor of Medicine
Assistant Medical Director
of the Clinical Trials Office
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

Amanda K Wagner, APRN-CNP, AOCNP
GI Malignancies
The James Cancer Hospital
The Ohio State University
Columbus, Ohio

Mark Yarchoan, MD
Associate Professor of Medical Oncology
Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center
Baltimore, Maryland

Neil Love, MD
Research To Practice
Miami, Florida

Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Incyte Corporation, and Taiho Oncology Inc during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24-28, 2024 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Eastern Time
5:30 AM – 6:00 AM — Registration
6:00 AM – 7:30 AM — NCPD Breakfast Meeting

What I Tell My Patients About ...

The Current and Future Use of Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC)

  • Long-term outcomes with traditional treatment approaches for early-stage HCC; clinical features that impart a high risk of disease recurrence
  • Historical data with adjuvant therapeutic approaches, such as sorafenib, for patients with HCC
  • Design, eligibility criteria and key endpoints of the Phase III IMbrave050 study of atezolizumab in combination with bevacizumab for patients with high-risk HCC after curative resection or ablation
  • Improved recurrence-free survival with adjuvant atezolizumab/bevacizumab compared to active surveillance in the IMbrave050 trial; clinical and research implications
  • Other ongoing Phase III studies evaluating adjuvant immune checkpoint inhibitor therapy for HCC

The Potential Role of Immunotherapeutic Strategies for Intermediate-Stage HCC

  • Historical outcomes associated with locoregional treatments, such as transarterial chemoembolization (TACE), for patients with intermediate-stage HCC
  • Design, eligibility criteria and key efficacy and safety endpoints of the Phase III EMERALD-1 trial comparing durvalumab in combination with TACE with or without bevacizumab to TACE alone for patients with locoregional HCC not amenable to curative therapy
  • Recently presented findings indicating a progression-free survival advantage with durvalumab, TACE and bevacizumab compared to TACE alone in the EMERALD-1 trial
  • Potential clinical role of durvalumab with TACE and bevacizumab in therapy for intermediate-stage HCC

First-Line Therapy with Atezolizumab/Bevacizumab for Advanced HCC

  • Biological rationale for combining anti-PD-1/PD-L1 and anti-VEGF antibodies for advanced HCC
  • Long-term data with atezolizumab/bevacizumab as first-line therapy for unresectable HCC
  • Selection of patients for up-front treatment with atezolizumab/bevacizumab
  • Role of atezolizumab/bevacizumab in therapy for patients who would not have qualified for participation in the pivotal trial, such as those with Child-Pugh B disease

First-Line Therapy with Durvalumab/Tremelimumab for Advanced HCC

  • Rationale for the combination of anti-PD-1/PD-L1 antibodies with anti-CTLA-4 antibodies for advanced HCC
  • Long-term efficacy and safety outcomes, including updated overall survival results, reported with durvalumab/tremelimumab for previously untreated advanced HCC
  • Advantages and disadvantages of dual immune checkpoint inhibitor therapy compared to other evidence-based front-line options for unresectable HCC
  • Selection of patients for up-front durvalumab/tremelimumab

Toxicities and Other Practical Considerations with Immune Checkpoint Inhibitor-Based Regimens for HCC

  • Spectrum, incidence and severity of immune-related adverse events (AEs) and other toxicities observed with anti-PD-1/PD-L1 antibodies for HCC
  • Effects on tolerability of administering anti-PD-1/PD-L1 antibodies in combination with other systemic therapies, such as anti-angiogenic agents or anti-CTLA-4 antibodies, for HCC
  • Algorithms for monitoring and managing immune-related and other AEs with immune checkpoint inhibitors for patients with HCC
  • Recommended dosing schedules for up-front atezolizumab/bevacizumab and durvalumab/tremelimumab
  • Role, if any, for rechallenging with immune checkpoint inhibitor therapy after relapse on first-line atezolizumab/bevacizumab or durvalumab/tremelimumab

The Role of Anti-PD-1/PD-L1 Antibodies in the Management of Advanced Biliary Tract Cancers (BTCs)

  • Long-term outcomes achieved with historical approaches to up-front treatment for advanced BTCs
  • Pivotal findings with the addition of durvalumab to first-line chemotherapy for advanced BTCs
  • Published results with pembrolizumab combined with cisplatin/gemcitabine as first-line treatment for advanced BTCs
  • Optimal integration into practice of up-front chemoimmunotherapeutic strategies for patients with advanced BTCs

The Importance of Biomarker Testing in the Care of Patients with Advanced BTCs

  • Spectrum and clinical relevance of genomic aberrations in patients with advanced BTCs
  • Prevalence of targetable molecular alterations in various BTCs: Intrahepatic cholangiocarcinoma versus extrahepatic cholangiocarcinoma versus gallbladder cancer
  • Available platforms for and optimal timing of genomic evaluation
  • Variable capacity of genetic testing methods to accurately identify different abnormalities

The Role of FGFR Inhibitors in the Management of Advanced Cholangiocarcinoma

  • Mechanistic similarities and differences between the approved FGFR inhibitors pemigatinib and futibatinib for advanced cholangiocarcinoma
  • Principal findings with pemigatinib and with futibatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
  • Evidence-based selection and sequencing of pemigatinib and futibatinib for FGFR-altered cholangiocarcinoma
  • Ongoing Phase III trials evaluating FGFR inhibition for patients with treatment-naïve cholangiocarcinoma

Tolerability and Other Considerations with FGFR Inhibitors for Cholangiocarcinoma

  • Comparative tolerability profiles of the approved FGFR inhibitors for cholangiocarcinoma; implications for therapeutic selection
  • Pathophysiology of the ocular toxicities observed with pemigatinib and futibatinib; monitoring and management protocols
  • Incidence and management of other common AEs reported with pemigatinib and futibatinib, such as hyperphosphatemia, nail changes, stomatitis, hand-foot syndrome and dry skin
  • Role, if any, of rechallenging with an FGFR inhibitor for patients who have experienced disease progression on FGFR inhibitor therapy

The Potential Role of HER2-Targeted Therapy for BTCs

  • Incidence of HER2 overexpression in patients with BTCs
  • Mechanism of action of the novel HER2-targeted bispecific antibody zanidatamab
  • Recent pivotal trial findings with zanidatamab for previously treated advanced or metastatic HER2-positive BTCs
  • Key efficacy and safety findings with trastuzumab deruxtecan for patients with previously treated HER2-positive BTCs
  • Current off-protocol and potential future role of HER2-targeted therapy for advanced BTCs

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hepatobiliary cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recall recently presented clinical trial results with combined anti-PD-L1 antibody and anti-VEGF therapy for patients with hepatocellular carcinoma (HCC) and a high risk of recurrence after curative resection or ablation or those receiving transarterial chemoembolization for unresectable disease, and consider the potential role of these strategies in clinical practice.
  • Appreciate available Phase III data with novel first-line therapies for unresectable or metastatic HCC, and discuss how these regimens can be optimally integrated into patient care.
  • Establish an evidence-based approach to the selection and sequencing of therapeutic options for patients with progressive HCC.
  • Discuss the biological justification for the evaluation of immune checkpoint inhibitors for advanced biliary tract cancers (BTCs), and counsel patients about the risks and benefits of these first-line approaches.
  • Assess key data sets supporting the FDA approvals of FGFR inhibitors for unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement.
  • Evaluate clinical trial findings with HER2-directed therapies for HER2-positive BTCs, and assess the current and potential utility of these treatments for appropriately selected patients.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Wagner — No relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms LedezmaSpeakers Bureaus: AstraZeneca Pharmaceuticals LP, Lilly. Dr SteinAdvisory Committees: AbbVie Inc, Eisai Inc, Genentech, a member of the Roche Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Merck; Data and Safety Monitoring Boards/Committees: Aethlon Medical Inc, Genentech, a member of the Roche Group. Dr YarchoanConsulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group; Co-Founder with Equity: Adventris Pharmaceuticals; Research Funding (to Johns Hopkins): Bristol Myers Squibb, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Incyte Corporation, and Taiho Oncology Inc.

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence Ballroom (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2024 ONS Congress and is connected to the Walter E Washington Convention Center by an underground concourse.


This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hepatobiliary cancers.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.

Registration for this event is independent of registration for the 2024 ONS Congress.

IN-PERSON Registration for nurses and other healthcare providers

I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.